The Federal Reserve Bank of New York and the Bank for International Settlements (BIS) jointly released a research report titled "Project Pine," testing the feasibility of implementing monetary policy using smart contracts in a tokenized financial market. The Project Pine research report shows that the New York Fed's Innovation Center and the BIS Innovation Hub jointly developed a prototype toolkit for central bank monetary policy implementation based on smart contracts. This toolkit supports operations such as interest rate payments, asset purchases, and collateral management, and has been tested in 10 historical simulation scenarios, including market turbulence and liquidity tightening. The report points out that smart contracts have the ability to quickly deploy and adjust monetary policy tools, providing flexibility and efficiency for future central bank policy execution in a tokenized financial system, but also emphasizes the need to focus on interoperability, data standards, and potential operational risks.
New York Fed and Bank for International Settlements Release Research Report Testing Tokenized Monetary Policy Tools
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
